Indefinite Delivery Contract HHSN261201700011I

Alchem Laboratories Corporation was awarded a single award indefinite delivery contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The contract has a potential value of $12,069,385 and a period of performance through April 10, 2028. The contract aims to procure analysis and synthesis of Good Manufacturing Practice and non-GMP bulk drugs and pharmaceutical formulations to support the National Cancer Institute's...

The National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, awarded a single award Indefinite Delivery Contract to Alchem Laboratories Corporation. The contract has a potential value of $7,777,665 and a period of performance from September 2017 to September 2022. Under the contract, Alchem Laboratories Corporation provides non-good manufacturing practices synthesis of small molecules to support the National Cancer Institute's...

This single-award IDV was issued by the National Cancer Institute, part of the Department of Health and Human Services, on April 11, 2023 with a potential value of $12.1 million. The contract aims to procure analysis and synthesis of GMP and non-GMP bulk drugs and pharmaceutical formulations to support the Institute's research efforts. Research Triangle Institute was selected as the prime contractor to deliver the required products and services over a five-year ordering period ending April 10,...

The key products and services being delivered under this federal contract IDV award from the National Cancer Institute (NCI) are preclinical toxicology studies on small molecule drug candidates for cancer and other indications. The prime contractor, IIT Research Institute (IITRI), a division of the Illinois Institute of Technology, will conduct non-GLP and GLP toxicology assessments in mice and dogs to support Investigational New Drug (IND) applications. IITRI holds several significant IDIQ...

Societal Cdmo San Diego, LLC, a small disadvantaged business and subsidiary of Irisys, Inc., was awarded an Indefinite Delivery Contract by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract, valued up to $6 million, is for the SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL services to support the NCI's cancer research and drug development programs. Under this Indefinite Delivery Contract,...

The National Cancer Institute (NCI), part of the Department of Health and Human Services, has awarded an Indefinite Delivery Contract (IDC) valued at $29,800,000 to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The contract, titled "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS," has a period of performance from September 22, 2015 to September 21, 2018. Under this multiple-award IDC, The Institute for...

The National Institutes of Health National Cancer Institute awarded a single-award indefinite delivery/indefinite quantity contract to ASE Direct, Inc. to procure erlotinib hydrochloride tablets in support of cancer research efforts. The contract has a potential value of $6.6M over a three-year ordering period ending January 2023. ASE Direct will supply 25mg, 100mg, and 150mg tablet formulations of the cancer drug under firm fixed price delivery orders, with performance at its facility in...

The Department of Health and Human Services National Institutes of Health (NIH) awarded an Indefinite Delivery Contract (IDC) to Alchem Laboratories Corporation, doing business as Alchem Laboratories Corp, to provide drug formulation and manufacturing services. The $45,000,250 multiple-award IDC was partially set aside for small businesses and has a period of performance through September 2024. Under this IDC, Alchem Laboratories has been issued task orders to synthesize non-GMP small molecule...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded an indefinite delivery contract to Regimed Medical as a total small business set-aside. The contract has a potential value of $6.34M over a four-year ordering period to procure nilotinib tablets in support of the Division of Cancer Treatment and Diagnosis. Three delivery orders have been awarded against this contract to date. The first was awarded on March 27, 2023 for $951K to provide...

The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...